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Retinal ganglion cellsPhotoswitches are traditional pharmacologic agonists, antagonists, or channel blockers that are covalent-
ly modiﬁed with an azobenzene derivative. Azobenzene undergoes wavelength-dependent isomerization
between cis and trans conformation. For some photoswitches, only one of these conﬁgurations is
biologically active, resulting in light-dependent activation or inhibition of function. Photoswitches that
feature a quaternary ammonium coupled to the azobenzene moiety cause light-dependent neuronal
depolarization due to blockage of voltage-gated potassium channels. Two photoswitch strategies have
been pursued. In the one-component strategy, the photoswitch is applied to native receptors; in the
two-component strategy, the photoswitch is combined with virally-mediated expression of a genetically
modiﬁed receptor, to which the photoswitch may covalently bind. The former approach is simpler but the
latter allows precise anatomic targeting of photoswitch activity. Acrylamide-azobenzene-quaternary
ammonium (AAQ) is the prototypical ﬁrst-generation one-component photoswitch. When applied to reti-
nas with outer retinal degeneration, ganglion cell ﬁring occurs in response to blue light, and is abrogated
by green light. In vivo, AAQ restored pupillary light responses and behavioral light responses in blind ani-
mals. DENAQ is a prototypical second generation one-component photoswitch. It features spontaneous
thermal relaxation so cell ﬁring ceases in dark, and features a red-shifted activation spectrum. Interest-
ingly, DENAQ only photoswitches in retinas with outer retinal degeneration. MAG is a photoswitched glu-
tamate analog which covalently binds to a modiﬁed ionotropic glutamate receptor, LiGluR. When applied
together, MAG and LiGluR also rescue physiologic and behavioral light responses in blind mice. Together,
photoswitch compounds offer a potentially useful approach to restoration of vision in outer retinal
degeneration.
 2015 Elsevier Ltd. All rights reserved.1. Introduction In theory, if one could recapitulate the native temporal ﬁringAcquired outer retinal degeneration associated with age-related
macular degeneration is the leading cause of blindness in the Unit-
ed States and most of the developed world, while outer retinal
degeneration associated with retinitis pigmentosa is the leading
inherited cause of blindness. Blindness in both conditions results
from irreversible loss of the rod and cone photoreceptors from
the outer retina. The remaining retinal cell types – bipolar cells,
horizontal cells, amacrine cells, Muller cells, and retinal ganglion
cells – remain viable (although signiﬁcantly rewired (Marc &
Jones, 2003)).pattern of each retinal ganglion cell in response to a dynamic visual
scene, one could ‘restore’ vision to a retina devoid of rods and
cones. Progress has been made on several approaches to this goal.
Embryonic or inducible progenitor stem cells can be differentiated
to a retinal fate and transplanted; this approach restores some light
sensitivity in mouse models of retinitis pigmentosa (Lamba, Gust,
& Reh, 2009). Second, external stimulation of retinal ganglion cells
by opto-electronic prosthetics has also advanced signiﬁcantly in
the past decade, with Food and Drug Administration approval of
the Argus II device, capable of restoring some visual phenomena
when implanted in profoundly blind individuals (Ahuja et al.,
2011; Humayun et al., 2012). Third, virally-mediated gene therapy
approaches using optogenetics, including channelrhodopsin and
halorhodopsin to excite and suppress retinal cells, respectively,
have advanced in the past decade, and have also been shown to
restore vision-like function to mice with advanced outer retinal
degeneration (Ivanova, Roberts, et al., 2010; Lagali et al., 2008;
Tomita et al., 2007).
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restoration in the foreseeable future. However, all share a common
feature of effective irreversibility. Once stem cells are placed in the
subretinal space, or viral gene therapy vectors introduced into the
eye, these alterations are effectively permanent. Similarly, it would
be challenging to replace an optoelectronic prosthesis once surgi-
cally implanted in the eye. Given the barriers to demonstration
of efﬁcacy and regulatory approval of any prosthetic or pharmaco-
logic approach, the irreversibility of these treatments makes itera-
tive progress in this ﬁeld challenging.
Over the past 8 years, a new approach has been advanced for
vision restoration. Compounds such as tetra-ethyl-ammonium
which block voltage-gated potassium channels have been known
for over a half century to induce neuronal cell ﬁring when admin-
istered extracellularly (George & Johnson, 1961). By linking these
agents to a photo-isomerizable moiety (azobenzene), novel com-
pounds have been produced that can activate neurons in a light-
dependent fashion. When applied to retinas with outer retinal
degeneration, these compounds are capable of inducing light-de-
pendent ﬁring of remaining retinal ganglion cells. Such activation
may form the basis for reconstitution of vision in eyes with outer
retinal degeneration.2. Azobenzenes
The light-isomerizable moiety utilized in these compounds is
azobenzene (Fig. 1). This class of compounds was among the ﬁrstFig. 2. Structure of maleimide-azobenzene-quarternary ammonium (Mal-Azo-QA, or M
system. (A) Structure of MAQ in trans and cis conformation. (B) Schematic of two-compo
with light due to photoswitch activity. From: Mourot, Tochitsky, and Kramer (2013)) w
Fig. 1. Chemical structure of azobenzene in trans and cis conformations.described in organic chemistry, having been characterized by Eil-
hard Mitscherlich in 1834. Azobenzenes are produced by reduction
of nitrobenzene; originally this was accomplished with iron ﬁlings
as catalyst (more recent methods utilize zinc). Azo dyes were
extensively used throughout the late 19th and early 20th century
in industry to color clothing and foodstuffs.
The property of azobenzene and its derivatives that renders it
useful for photopharmacology is the photoisomerization of cis
and trans isomers. The isomers can be interchanged with speciﬁc
wavelengths of light. The trans-to-cis conversion utilizes short
wavelength light (typically ultraviolet for unsubstituted azoben-
zene), while the cis-to-trans isomerization occurs under longer
wavelength light (blue light for the unsubstituted azobenzene).
The cis isomer is less stable than the trans and so cis-azobenzene
will thermally convert back to the trans in dark. Photoisomeriza-
tion of trans to cis azobenzene is extremely rapid (on the order of
picoseconds), while the reversion in dark of cis to trans takes hours
for unsubstituted azobenzene. However, substitution of electron-
withdrawing groups can alter both the thermal stability of the
cis-form, as well as the action spectrum for isomerization
(Banghart, Volgraf, & Trauner, 2006). Because of these properties
azobenzene derivatives have been used in a variety of nanotech-
nology applications ranging from surface holography, liquid crystal
displays, and optoelectronics (Brehmer et al., 1997; Choi et al.,
2007; Matharu, Jeeva, & Ramanujam, 2007; Nakatsuji, 2004;
Oliveira et al., 2005).
The ﬁrst successful application of azobenzene-mediated control
of a potassium channel blocker was the development of the SPARK
channel (Chambers et al., 2006). SPARK stands for synthetic photoi-
somerizable azobenzene-regulated potassium channel. In this
approach, Chambers et al. synthesized a modiﬁed Shaker potassi-
um channel (including an EGFP tag for visualization). In one ver-
sion, the Shaker channel was left in its native, potassium
conducting form (H-SPARK), while in another a point mutation
converted the channel to a non-speciﬁc cation channel capable of
conducting extracellular sodium (D-SPARK). The small molecule
photoswitch employed was maleimide-azobenzene-quaternary
ammonium (MAL-AZO-QA), with the latter moiety responsibleAQ), the small molecule photoswitch used in the two-component SPARK channel
nent blockade under trans conformation. (C) Example of change in cell conductivity
ith permission.
Fig. 3. Structure of acrylamide-azobenzene-quarternary ammonium (AAQ).
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covalent coupling of the compound to a cysteine on the cell
surface.
SPARK-expressing CHO cells showed no change in channel func-
tion prior to addition of 300 lM MAL-AZO-QA, and light had no
effect on these cells without presence of both transgenic channel
and azobenzene-based photoswitch. However, after transfection
and administration of MAL-AZO-QA, expected changes in the slope
of the current–voltage relationship of patched clamped cells for
both D-SPARK and H-SPARK were observed. Further, D-SPARK-ex-
pressing cells showed hyperpolarization when cells were changed
from 390 nm light to 505 nm light, and depolarization with the
opposite lighting change. The opposite effect was seen with H-
SPARK channels (i.e. depolarization with the UV? blue-green
lighting change). Cells expressing GFP only or without MAL-AZO-
QA showed no changes. When tested in mammalian hippocampal
cells in culture, cells transfected with D-SPARK and treated with
MAL-AZO-QA showed light-dependent action potential ﬁring in vit-
ro. Taken together, these results established that an azobenzene-
based small molecule potassium channel blocker is capable of
inducing light-dependent cell ﬁring in mammalian neurons.
The SPARK system constitutes a ‘two-component’ photoswitch,
requiring both transgenic expression of a modiﬁed receptor and
addition of the small molecule photoswitch. Subsequent research
has pursued both this two-component approach, as well as a
one-component approach which does not require genetically mod-
iﬁed channels.3. One component photoswitches
The ﬁrst milestone in development of one-component photo-
switches was the synthesis of AAQ (Banghart et al., 2009; Fortin
et al., 2008, 2011). Where MAQ had a maleimide group at its distal
end, AAQ substituted an acrylamide (Fig. 3). This compound was
capable of photosensitizing wild-type voltage gated potassium
channels. In vitro studies suggested that AAQ induced light-
dependent blockade of a variety of Kv potassium channels (Fortin
et al., 2008). Initially, it was thought the compound bound on theFig. 4. Reconstitution of retinal ganglion cell ﬁring to rd1/rd1mouse retina by addition of
multi-electrode array raster, with each line representing one ganglion cell. Note strong ﬁ
(2012) with permission.extracellular side of the receptor, where the acrylamide moiety
could bind covalently to the receptor surface; however, subsequent
studies suggested that AAQ acts on the internal binding site and
does not require covalent attachment to function (Banghart et al.,
2009). Initial studies were performed on hippocampal slice prepa-
rations (Fortin et al., 2008). Light-dependent cell ﬁring was
observed after addition of micromolar extracellular AAQ. Green
light (530 nm) resulted in cell ﬁring, while use of short wavelength
light (390 nm) resulted in silencing of activity.
These characteristics suggested that AAQ might be used to
restore light-dependent ﬁring of retinal ganglion cells in animals
with outer retinal degeneration. Using isolated retina from rd1/
rd1 mutant mice (with extensive outer retinal degeneration),
Polosukhina et al. (2012) demonstrated that AAQ application
restored light-dependent ﬁring activity to these mice as assayed
by multi-electrode array recording (Fig. 4). Interestingly, the spec-
tral sensitivity of AAQ-activated retina was reversed from that seen
in hippocampus: short wavelength light (380 nm) activated cell
ﬁring, while longer wavelength light (500 nm) abrogated ﬁring.
Retinas activated by 380 nm light showed ﬁring activity of many
seconds on direct transition to dark, reﬂecting the slow thermal
relaxation of trans to cis conformation. The observed spectral sen-
sitivity was reversed when retinas treated with GABAergic and
glycinergic blockade were tested following AAQ application. In this
case, retinal ganglion cell ﬁring was reduced in 500 nm light, and
minimally affected by 380 nm light. This result suggests that the
primary effect of AAQ on the retina is to light activate amacrine
cells, which in turn inhibit retinal ganglion cell ﬁring. Other inter-
pretations are possible, however, including the possibility that the
cis form of AAQ blocks channels present in retinal ganglion cells of
degenerated retina.
The intensity of light required to activate ﬁring was relatively
bright, beginning at about 1015 photos/cm2/s and reaching mid-
point at 1016 photos/cm2/s. In this study, the authors were also
able to look at receptive ﬁelds of activated cells. They found a posi-
tive ‘photoswitch index’ (a measure of relative ﬁring rates in light
before and after administration of the photoswitch compound)
when measuring cells within 200 lm of the light target, but did
not see positive switching for cells further away. This conﬁrms
the suggestion that AAQ effect reﬂects the local light environment
on the retina.
Several assays were employed to determine whether AAQ-
mediated light-induced retinal ganglion cell ﬁring resulted in
signals interpretable by the central nervous system of blind mice.
rd1/rd1;opn4/ mice lack pupillary light responses (Panda et al.,
2003). Following intravitreal administration of 1 lL of 80 mMAAQ, as measured by multi-electrode array (MEA) recording. Upper panel in each is
ring under UV light and relative silencing under green light. From: Polosukhina et al.
Fig. 5. Structure and absorption spectra of second generation photoswitches. From: Mourot et al. (2011) with permission.
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approximately 35% of animals. In a second behavioral assay of
negative phototaxis (modiﬁed from (Johnson et al., 2010)), in
which time to turn from a bright light stimulus is measured, rd1/
rd1;opn4/ demonstrated no negative phototaxis, but the same
mice showed signiﬁcant light aversion following intraocular injec-
tion of AAQ.
Taken together, these results demonstrated (1) azobenzene-
based potassium channel blockers are capable of restoring light-
dependent ﬁring activity to retinal ganglion cells of animals blind
from outer retinal degeneration, and (2) these signals are at least
crudely interpreted by the brain and can inﬂuence physiology
and behavior.
AAQ has several drawbacks as an agent which make further
development for potential human use problematic. First, AAQ is
activated by light of 380–400 nm. The human lens ﬁlters the vast
majority of these wavelengths and so achieving the bright intensi-
ties necessary for AAQ activation at the level of the retina would be
problematic. Second, the slow relaxation of AAQ in dark would
require switching between short and long wavelengths (with an
attendant auxiliary visual stimulating device). Third, the presence
of the acrylamide moiety on AAQ raises the possibility of neuro-
toxicity (although this has primarily been associated with the
monomeric form of acrylamide (Spencer & Schaumburg, 1974a,
1974b, 1975)).
4. Second generation one-component photoswitches
To address these limitations of AAQ, the Trauner laboratory
synthesized a series of ‘second generation’ one-component
photoswitches by substituting the azobenzene moiety with moreelectrophilic groups (Fig. 5). These substitutions result in substan-
tial red-shifting of the action spectrum these compounds, broaden-
ing of their activation spectrum, and rapid relaxation in dark
(Mourot et al., 2011). One compound, with a diethylammonium
substituted for the acrylamide (DENAQ) had reasonable solubility
and was selected for further testing.
In vitro, DENAQ showed good activation of retinal ganglion cells
of rd1/rd1mice with robust ﬁring in response to light from 360 nm
to over 500 nm (Fig. 6) (Tochitsky et al., 2014). DENAQ-activated
retina also showed higher sensitivity than AAQ, with light respons-
es ex vivo starting in the mid 1013 photons/cm2/s range of intensity.
Following a single intravitreal injection, light responses could be
elicited from treated retinas for 3–4 days.
Surprisingly, DENAQ did not affect function of wild-type retinas,
and did not appear to induce photoswitching in these retinas. The
same lack of effect was seen ex vivo in retinas under glutamatergic
blockade, isolating the retinal ganglion cells. This strongly suggest-
ed that some aspect of retinal degeneration was creating an oppor-
tunity for DENAQ to act, either through an upregulated channel or
perhaps by increased access for the drug into retinal cells.
Tochitsky et al. (2014) found that that the Ih conductance, mediat-
ed by the HCN channel, was photoswitched in rd/rd retinas but not
in retinas from wild-type animals. Use of HCN channel blockers
ivabradine and cilobridine attenuated or eliminated DENAQ-in-
duced photoswitching, providing additional supporting evidence
for the HCN conductance being a major target of DENAQ activity.
In vivo, intravitreal injection of DENAQ in rd/rd mice resulted in
altered free range behavior (with increasing activity in light).
Additionally, rd/rd mice injected with DENAQ were able to associ-
ate light exposure with a noxious stimulus in a learning paradigm,
performing equivalently to wild-type animals in this assay.
Fig. 6. Conferral of light sensitivity on retinal ganglion cells of rd1/rd1mice by DENAQ. (A) Structure of DENAQ. (B) Multi-electrode array recording of rd1/rd1 retina prior to
DENAQ administration. (C) Recording from rd1/rd1 retina post-administration of DENAQ. Note cessation of ﬁring in dark. From: Tochitsky et al. (2014) with permission.
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Development has proceeded as well with two-component pho-
toswitches. In this paradigm, treatment of blind retina entails both
gene therapy with a genetically modiﬁed cell surface receptor, and
administration of a photoswitch speciﬁc for that receptor. Unlike
introduction of transgenic photoreceptors for treatment of blind-
ness, this hybrid approach allows for native signal transduction
and ampliﬁcation mechanisms, and additionally has lower theore-
tical chance of eliciting a long-lasting autoimmune response to for-
eign protein. Given the central importance of glutamatergic
signaling in the retina (Brandstatter, 2002; Thoreson &
Witkovsky, 1999), development of two component photoswitches
for treatment of blindness has, to date, centered on glutamate
receptors and synthetic photoswitch ligands.
LiGluR is a recombinant ionotropic glutamate receptor (analo-
gous to SPARK) with an attachment site for a synthetic ligand,
MAG (maleimide-azobenzene-glutamate, Fig. 7) (Volgraf et al.,
2006). When transfected into HEK293 cells, LiGluR had minimal
effect by itself. Similarly, application of MAG alone had no effect
on untransfected 293 cells. However after conjugation of MAG in
LiGluR-transfected cells, strong cationic currents were induced in
cells with light stimuli. Similar results were obtained when hip-
pocampal neurons were transfected in vitro with LiGluR6 and con-
jugated with MAG (Szobota et al., 2007). Even very high frequency
light (>80 Hz) resulted in matching action potentials.
To test the utility of the LiGluR/MAG two component system in
the treatment of blindness, Caporale et al. (2011) cloned the LiGluR
receptor into an adeno-associated viral vector (AAV) under control
of a synapsin promoter (driving expression in retinal ganglion cells
following intravitreal injection), and applied virus to eyes of rd1/
rd1 mice. Retinas harvested from these animals demonstrated
light-dependent ﬁring in response to 380 nm light but not500 nm light. Following intravitreal injection, MAG restored brisk
and complete pupillary light responses to gnat1/;cnga3/;op-
n4
/
mice (mice lacking rod transducing and cone cyclic-gated
nucleotide channel, and hence blind to light, as well as lacking mel-
anopsin and non-visual signaling). Electrophysiologic visual
evoked potentials (VEP) were restored to rd1/rd1 animals after
LiGluR viral infection and MAG at levels approximately 50% of
wild-type. Additionally, light avoidance, as measured in a water-
maze paradigm, was restored in rd1/rd1 animals following treat-
ment with LiGluR and MAG.6. Relative advantages and disadvantages of photoswitch
activation of retinal ganglion cells as a treatment for blindness
Taken together, results to date demonstrate that both one- and
two-component photoswitch methods are capable of conferring
light-dependent ﬁring activity on retinal ganglion cells in mice
with near complete outer retinal degeneration. This activity
appears sufﬁcient to restore light-dependent physiologic activity
such as pupillary light response, to mice from outer retinal degen-
eration in vivo. Application of these techniques also restores behav-
ioral light sensitivity, including negative phototaxis and light-
dependent associative learning. It is important to note that, to date,
no study has demonstrated restoration of form vision (as manifest
by optokinetic reﬂex, for instance, or associative learning based on
a true visual stimulus).
Functionally, photoswitch techniques have the same end-goal
as opto-electronic prostheses (Ahuja et al., 2011; Barry, Dagnelie,
& Argus, 2012; Humayun et al., 2012; Mandel et al., 2013; Rizzo
et al., 2011; Stingl et al., 2013; Zrenner, 2013), namely converting
light stimuli directly into retinal ganglion cell stimulation. The suc-
cess of these implants in restoring some form vision bodes well for
Fig. 7. Structure of maleimide-azobenzene-glutamate (MAG, left) and proposed mechanism of action on ionotropic glutamate receptors. From: Volgraf et al. (2006) with
permission.
R.N. Van Gelder / Vision Research 111 (2015) 134–141 139the potential of small molecule photoswitches to accomplish the
same. Both techniques have complementary strengths and weak-
nesses. Opto-electronic devices can incorporate ampliﬁcation cir-
cuitry to boost signal in dim light, while photoswitch compounds
would require brighter light for the same effect. However, photo-
switch compounds have the advantage of potentially conferring
light sensitivity on every retinal ganglion cell, without concern
for cross-talk induced by external electrical ﬁelds. Additionally,
administration of photoswitch compounds and viral vectors will
likely occur by simple intravitreal injection, as opposed to the sig-
niﬁcant epiretinal or subretinal surgery required for implantation
of an optoelectric prosthesis.
Gene therapeutic approaches offer another means for confer-
ring light sensitivity on retinal ganglion cells, bipolar cells, or
non-degenerated photoreceptors (Busskamp et al., 2010, 2012;
Ivanova, Hwang, et al., 2010; Ivanova, Roberts, et al., 2010;
Ivanova & Pan, 2009; Tomita et al., 2007). Compared to one-com-
ponent photoswitch these approaches allow more speciﬁc target-
ing to subsets of remaining cells in the retina. For instance,
targeting to cone pedicles may allow substantial retinal processing
of signal and reconstitution of faithful action potential trains to
visual stimuli (Busskamp et al., 2010). Gene therapy approaches
are also potentially permanent. However, to date channelopsin
and halopsin techniques have required more light intensity than
is required for photochemical approaches. The permanence of gene
therapy approaches may also be a liability as there is likely not
opportunity for ‘upgrading’ to an improved channel. There are still
theoretical concerns as well over the possibility of long-term uvei-
tis resulting from high level expression of foreign channel proteins
in the retina, although this has not been observed in animal studies
to date.
Relative to each other, one-component and two-component
systems are complementary in strengths and weaknesses. The
one component system is simpler, with lower potential for toxicity
given the single component. However, targeting is limited by dis-
tribution of the target of the photoswitched compound, which
may encompass many cell types. Conversely, the two component
system allows precise targeting of the photoswitch, but requires
gene therapy in addition to photoswitch compound. From a practi-
cal perspective, regulatory approval of a single component photo-
switch is likely to be more expeditious than a two-component
system.7. Frontiers in photochemical restoration of blindness
For one-component systems, a major challenge to translation
for human use is the solubility of photo-switch compounds. Future
development will be targeted at improving the solubility of these
compounds, perhaps by using uncharged moieties rather than
the charged, quaternary ammonium. Ultimately, a sustained
release delivery device, similar to a Retisert might be required to
maintain a steady and sufﬁcient supply of photoswitch to the reti-
na (Jaffe et al., 2000). Delivery of one-component compounds could
also be improved by utilizing large cellular pores, an approach
which has been used successfully to load the QAQ photoswitch (-
containing two, charged quaternary ammonia) (Mourot et al.,
2012).
A range of additional compounds, targeting other pathways
including GABAergic and TRP channel pathways, may be rendered
photoswitchable as well (Kienzler et al., 2013; Reiter et al., 2013;
Schonberger & Trauner, 2014; Stein et al., 2012, 2013). Some of
these may have high speciﬁcity for certain visual processing path-
ways. An ideal target might be an mGluR6-speciﬁc photoswitch,
given its speciﬁcity for speciﬁc bipolar pathways (Snellman et al.,
2008).
For two-component system, MAG’s activation at 380 nm is too
short to be useful in a phakic human eye (van de Kraats & van
Norren, 2007). Red shifted MAG has now been synthesized and
shown to be efﬁcacious (Kienzler et al., 2013), which will alleviate
this shortcoming. Improvements in viral vector targeting through
directed selection will help improve cell-type speciﬁcity following
intravitreal injection (Dalkara et al., 2013). And, as was the case for
the one-component switches, additional channels may be targeted
for two component function, potentially including metabotropic
receptors (Schonberger & Trauner, 2014) which would allow signal
ampliﬁcation, which in turn could improve sensitivity.
For all vision restoration techniques, one major hurdle is deter-
mining the extent to which a non-native action potential series can
be interpreted by the vision processing centers of the brain. The
normal retina performs a great deal of signal processing, including
directional motion detection, color surround processing, and wide-
spread adaptation to lighting conditions, which are not intrinsic
features of ‘reanimated’ (and functionally reprogrammed) retinal
ganglion cells. While techniques that target upstream cells such
as bipolar cells may result in more native visual processing and
140 R.N. Van Gelder / Vision Research 111 (2015) 134–141ultimately action potential ﬁring, it still remains to be determined
if these signal sequences can be correctly interpreted as dynamic
visual scenes. It is conceivable that ﬁrst-generation use of photo-
switch compounds will also include a ‘visual processing unit’ that
would interpret a visual scene and stimulate photoswitch-activat-
ed retinal ganglion cells with particular light stimuli designed to
more faithfully reproduce normal retinal ganglion cell output. In
making such a processing unit user-tunable, it may be possible
to achieve better visual results. As an example, in primates the reti-
nal ganglion cells subserving the fovea, while having very high
resolution due to their one-to-one mapping the cones, are radially
displaced from the fovea proper (Curcio & Allen, 1990). As such, in
response to a visual scene presented normally to the retina, direct
stimulation of retinal ganglion cells would likely mis-map perifo-
veal stimulation to the center of vision, while producing a relative
scotoma for central vision (due to the lack of retinal ganglion cells
in the fovea proper). This could be corrected with a device that
converted a digital video image of the outside world to a raster-s-
can of appropriate wavelength, which would displace the true
foveal image to be projected on the appropriate retinal ganglion
cells. Similarly, the nature of color vision following photoswitch-
mediated retinal reanimation is not apparent (as all color-oppo-
nent ganglion cells would be stimulated equivalently), but again
any detriment to vision might be mitigated by an altered retinal
stimulation pattern to mimic native retinal ﬁring. This challenge
will be an active area for research (for all modes of vision restora-
tion) for years to come.8. Conclusion
In a relatively brief period of time since the ﬁrst proof-of-con-
cept that photoswitched channel blockers could induce light-de-
pendent neuronal ﬁring activity, the ﬁeld has progressed to
demonstration of partial reversal of blindness in animal models
using both one- and two-component systems. This approach is
complementary to other approaches in vision restoration, but
potentially offers very high resolution (conceivably every ganglion
cell), as well as (for the one-component system) the potential for
sequential improvement in agents for a single patient. Signiﬁcant
hurdles with respect to demonstration of safety, drug delivery,
and optimization of signaling to the visual pathways of the brain
remain before this system can be effectively applied to human
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